fda warning letters glp-1 compounders september 2025 warns telehealth providers over obesity drug marketing FDA ramps up its pushback

therefore, they do not interact with conventional medication in the same way that herbal medicine or other nutraceuticals do

It is an experimental compound that has been investigated for inflammatory bowel disease and soft tissue healing, although there is a concerning lack of published clinical trial data because studies appear to have been cancelled or stopped without any published conclusions

10.3389/fonc.2022.834729 65 LinR.ZhangZ.ChenL.ZhouY.ZouP.FengC.et al (2016)

Pre-clinical safety characterisation studies have documented a favourable safety profile for both BPC-157 and TB-500 across the dose ranges studied in rodent models

10.1038/373699a0 101 ShengH.ShaoJ.TownsendC